Brief: Inhibikase Therapeutics Announces Pre-IND Meeting With The FDA For IkT-001Pro In Pulmonary Arterial Hypertension
03/04/2024 14:19
April 3 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES PRE-IND MEETING WITH THE
FDA
FOR IKT-001PRO IN PULMONARY ARTERIAL HYPERTENSION
* INHIBIKASE THERAPEUTICS INC - MEETING WILL BE HELD ON
APRIL 5,
2024, WITH MEETING RESULTS TO BE REPORTED FOLLOWING RECEIPT OF
FORMAL MEETING MINUTES
Source text for Eikon: ID:nGNX9TFCVm
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary